Brand Name : Darbecure
Composition : Darbepoetin alfa
Strength availability : 25mcg
Manufactured by : Emcure Pharmaceuticals Ltd
Packing : 1ml in a Vial
for MORE INFORMATION !!!
Darbecure 25mcg is the trade name for darbepoetin alfa
Darbecure 25mcg is a biologic response modifier. It is an erythropoiesis stimulating protein.
Darbecure 25mcg injection causes the bone marrow to produce RBCs. If the body does not produce enough red blood cells, serious Anemia can occur. This often present in people with chronic kidney failure whose kidneys are not functioning properly.
Darbecure 25mcg is indicated for the treatment in patients with Anemia associated with chronic kidney disease (CKD).
Darbecure 25mcg is indicated for the treatment in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
Darbecure 25mcg is indicated for the treatment in patients with Symptomatic Anemia associated with myelodysplastic syndromes (MDS).
The recommended dose of this medicine will be varied for different patients.
Anemia from chronic kidney failure :
The dose preferred for adults and children – dose mainly based on body weight
The initial dose is 0.45 to 0.75 mcg/kg of body weight injected via IV or SC (under the skin) once a week or once every week.
Your doctor may adjust the dose as needed
Anemia from cancer chemotherapy :
For adult: dose is based on body weight
The initial dose is 2.25mcg once every 3 weeks injected under the skin.
The dose for children and use should be determined by your doctor
Darbepoetin alfa provoke erythropoiesis by the same mechanism as endogenous erythropoietin.
Erythropoietin combines with progenitor stem cells to raise red cell production. Binding of erythropoietin to the erythropoietin receptor causes to receptor dimerization, that facilitates activation of JAK-STAT indicating pathways within the cytosol.
Signal transducers and activators of transcription (Activated STAT) proteins are then translocated to the nucleus where they supply as transcription factors which controls the activation of genes contains in cell division or differentiation.
slow absorption and Time to peak plasma concentration is 34 hr subcutaneously (SC)
Bioavailability for adult is 37% SC and children is 54% SC
volume of distribution is 0.06L/kg
half-life is 46 hr (SC) and if IV then 21 hr.
Darbecure 25mcg injection will causes high mortality, myocardial infarction, stroke, and thromboembolism: Using ESAs to target a haemoglobin level of greater than 11 g/dL raises the risk of severe adverse cardiovascular reactions
Darbecure 25mcg injection will leads to known porphyria, sickle cell Anemia, thalassemia in patients
Reduction of dose if Hgb increase exceeds 1 g/dL in any 2-week period
Higher the mortality and/or increased risk of tumor progression or relapsed in patients with cancer
The drug has high risk for seizures in patients with CKD; increase monitoring of these patients for changes in seizure frequency or premonitory symptoms
If serious Anemia and low reticulocyte count occurs during treatment, withhold treatment and check out for pure red cell aplasia.
No drug interaction involved in the drug Darbecure 25mcg Injection
The patients contraindicated with Darbecure 25mcg injection causes
After treatment causes pure red cell aplasia
If dose is missed, have it soon before next dose reaches or skip the dose and follow normal timing
Please Consult with the doctor
Store at 2℃ – 8℃ (36℉ to 46℉)
Do not freeze
Protect from light and protect from light
The side effects caused by Darbecure 25mcg as follows;
Serious allergic reaction: wheezing, dizziness, skin rash, itching
Shortness of breath
Low blood pressure during dialysis
Pain in abdominal
Edema of the arms or legs